60 Degrees Pharma Updates Investor Deck with Cash, Trial Progress, and Profitability Targets
SXTP sits 24% above its 52-week low of $1.22 on light trading volume (0.2× avg).
Summary
60 Degrees Pharmaceuticals filed an updated investor presentation revealing $3.34M in cash as of March 31, 2026, near-complete enrollment in its pivotal babesiosis trial, and profitability targets of Q4 2026 (malaria) and 2028 (babesiosis).
Key Events · Earnings and Guidance · SXTP
-
Updated Investor Presentation Filed
The company furnished an updated investor presentation dated July 20, 2026, containing new financial data, clinical trial enrollment figures, and profitability targets.
-
Cash Position Disclosed
A snapshot of liquidity as of March 31, 2026, shows $3.34 million in cash and cash equivalents, following a $5M public offering in July 2025 and approximately $4M raised via ATM through March 2026.
-
Pivotal Trial Enrollment Nears Interim Analysis
The randomized placebo-controlled study of tafenoquine for hospitalized babesiosis patients has enrolled 23 of the minimum 24 patients required to trigger an interim analysis, with results expected to be disclosed before October 30, 2026.
-
Profitability Targets Set
The presentation targets profitability in Q4 2026 for the malaria prevention business and in 2028 for the babesiosis indication, contingent on clinical and commercial success.
Analysis · SXTP · Life Sciences
The updated investor presentation offers the first glimpse of the company's balance sheet as of March 31, 2026, revealing $3.34 million in cash against the backdrop of a critical 4-month cash runway disclosed in May. It also shows that the pivotal babesiosis trial has enrolled 23 of the minimum 24 patients needed for an interim analysis, with results expected by October 30, 2026. Concrete milestones are now on the table: profitability is targeted for Q4 2026 in the malaria business and 2028 for the babesiosis indication. Coming just weeks after a positive DSMB recommendation and amid an ongoing proxy fight over a proposed reverse stock split and dilutive share issuance, these financial and clinical updates carry heightened significance.
At the time of this filing, SXTP was trading at $1.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $1.22 to $8.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.